Drug Profile
Research programme: anti-interleukin monoclonal antibodies - AstraZeneca
Alternative Names: Anti-IL-17 MAb - AstraZeneca ; Anti-IL-18 MAb - AstraZeneca ; Anti-IL-1R MAb - AstraZeneca ; CAT-2200; MEDI-571Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 1 receptor antagonists; Interleukin 18 inhibitors; Interleukin-17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Gastrointestinal disorders; Inflammation; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in United Kingdom (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in United Kingdom (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in United Kingdom (Parenteral)